Relevance of a combined HIV antigen/antibody assay to detect early HIV infections in a low prevalence population: Case reports

Clinical Laboratory

Volumn 50, Issue 7-8, 2004, Pages 409-413

  Andersson, S ^a   Asjo B ^b   Jenum, P A ^c   Manner, I ^c   Njolstad G ^b   Ragnhildstveit, E ^d   Skaug, K ^e   Soderquist B ^a   Von Sydow, M ^f  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c VESTRE VIKEN HOSPITAL TRUST   (Norway)

^d Østfold Hospital Trust Fredrikstad   (Norway)

^e NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Confirmation; HIV Combo assays

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN;

ACUTE DISEASE; ADULT; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; DISEASE TRANSMISSION; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; INTERMETHOD COMPARISON; MALE; NORWAY; PREVALENCE; SENSITIVITY ANALYSIS; SEROCONVERSION; SWEDEN;

ADULT; AIDS SERODIAGNOSIS; FEMALE; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HUMANS; IMMUNOBLOTTING; MALE; MASS SCREENING; MIDDLE AGED; NORWAY; REAGENT KITS, DIAGNOSTIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SWEDEN;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 4344683926     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Gürtler L, Mühlbacher A, Michl U et al. Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. J Virol Meth 1998,75:27-38
2. Ly TD, Martin L, Daghfal A et al. Seven human immunodeficiency virus (HIV) antigen-antibody combination assays: evaluation of HIV seroconversion sensitivity and subtype detection. J Clin Microbiol 2001, 39:3122-3128
3. Sickinger E, Stieler M, Kaufman B et al. Multicenter evaluation of a new, automated enzyme-linked immunoassay for detection of human immunodeficiency virus-specific antibodies and antigen. J Clin Microbiol 2004, 42:21-29
4. Weber B, Berger A, Rabenau H, Doerr HW. Evaluation of a new combined antigen and antibody human immunodeficiency virus screening assay, VIDAS HIV DUO Ultra. J. Clin Microbiol 2002, 40:1420-1426
5. Zaaijer HL, Excel-Oehlers PV, Kraaijeveld T, Altena E, Lelie PN. Early detection of antibodies to HIV-1 by third generation assays. Lancet 1992, 340:770-772
6. Lindback S, Thorstensson R, Karlsson AC et al. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. AIDS 2000, 14:2333-2339
7. Gallarda JL, Henrard DR, Liu D et al. Early detection of antibody to human immunodeficiency virus type 1 by using an antigen conjugate immunoassay correlates with the presence of immunoglobulin M antibody. J Clin Microbiol 1992, 30:2379-2384
8. Lyles RH, Munoz A, Yamashita TE et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men: Multicenter AIDS Cohort Study. J Infect Dis 2000, 181:872-880
9. Mellors JW, Munoz A, Giorgi JV et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954
10. Lori F, Jessen H, Lieberman J et al. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis 1999, 180:1827-1832
11. Hoen B, Dumon B, Haric M et al. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial. J Infect Dis 1999, 180:1342-1346
12. Pilcher CD, Eton Jr JJ, Vemaza PL et al. Sexual transmission during the incubation period of primary HIV infection. JAMA 2001, 286:1713-1714
13. Quinn TC, Wawer MJ, Swankambo N et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1: Rakai Project Study Group. N Engl J Med 2000, 342: 921-929
14. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000, 356:1423-1430
15. Chun TW, Carruth L, Finzi D et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infections. Nature 1997, 387:183-188
16. Bozzette SA, Joyce G, McCaffrey DF et al. Expenditures for the care of HIV infected patients in the era of highly active antiretrovirals N. Engl J Med 2001, 23:1603-1614
17. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with infection. Ann Intern Med 2000; 4133:21-30
18. Hetherington S, McGuirk S, Powell G et al., Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001, 23:1603-1614
19. Martinez-Marino B, Ashlock BM, Shiboski S, Hecth FM, Levy JA Effect of IL-2 therapy on CD8+ cell noncytotoxic anti-HIV response during primary HIV-1 infection. J Clin Immunol 2004, 24:135-144